Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23749740 | 1.00 | TRPA1 (0.33) | TRPA1TRPM8L3MBTL1EPHX1MEN1 | |
| SCHEMBL29296274 | 0.88 | TRPA1 (0.31) | TRPA1TRPM8EPHX1MEN1ALDH1A1 | |
| SCHEMBL29296251 | 0.83 | MEN1 (0.34) | L3MBTL1MEN1ALDH1A1KMT2A | |
| SCHEMBL17449612 | 0.82 | L3MBTL1 (0.35) | TRPA1TRPM8L3MBTL1EPHX1MEN1 | |
| SCHEMBL22068530 | 0.82 | L3MBTL1 (0.35) | TRPA1TRPM8L3MBTL1EPHX1MEN1 | |
| SCHEMBL26170335 | 0.82 | L3MBTL1 (0.35) | TRPA1TRPM8L3MBTL1EPHX1MEN1 | |
| SCHEMBL13850490 | 0.82 | L3MBTL1 (0.35) | TRPA1TRPM8L3MBTL1EPHX1MEN1 | |
| SCHEMBL17973808 | 0.79 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL2706023 | 0.79 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL25685817 | 0.79 | L3MBTL1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | TRPA1 3633/4885TRPM8 2997/4885L3MBTL1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.